3-Methoxy-4-hydroxyphenylglycol excretion in acutely schizophrenic patients during a controlled clinical trial of the isomers of flupenthixol.
Urinary MHPG excretion in patients with acute schizophrenia was studied before and during a trial of the isomers of flupenthixol and placebo. Pretrial MHPG excretion was not related to severity of illness before the trial or to other pretrial clinical variables. In male subjects higher pretrial MHPG excretion was associated with a better outcome 1 year post-trial. However in females no relationship between MHPG excretion and outcome was established. During the trial there was a reduction in MHPG excretion in patients treated with beta-flupenthixol but no decrease in the group treated with alpha-flupenthixol or chlorpromazine. In patients on placebo there was a reduction in MHPG excretion in those who did well clinically, but not in those who did poorly. Thus low MHPG excretion may be a predictor of poor outcome in schizophrenia, but MHPG excretion also changes both as a function of clinical state and of neuroleptic drug administration.
D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D005475:Flupenthixol / Q000627:therapeutic use*; D006018:Glycols / Q000652:urine*; D006801:Humans; D007536:Isomerism; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000652:urine*; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy* / Q000652:urine; D013892:Thioxanthenes / Q000627:therapeutic use*
D006018:Glycols; D013892:Thioxanthenes; D008734:Methoxyhydroxyphenylglycol; D005475:Flupenthixol